Short Interest in Myriad Genetics Drops By 4.2% (MYGN)
Myriad Genetics (NASDAQ:MYGN) was the target of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 35,772,908 shares, a drop of 4.2% from the July 31st total of 37,357,915 shares, Analyst Ratings.Net reports. Based on an average daily trading volume, of 1,118,942 shares, the short-interest ratio is currently 32.0 days. Currently, 47.9% of the shares of the company are sold short.
Several analysts have recently commented on the stock. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Myriad Genetics in a research note on Friday, August 15th. They now have a $35.00 price target on the stock, down previously from $40.00. Separately, analysts at SunTrust raised their price target on shares of Myriad Genetics from $22.00 to $26.00 in a research note on Monday, July 14th. Finally, analysts at RBC Capital raised their price target on shares of Myriad Genetics from $31.00 to $40.00 in a research note on Monday, June 30th. They now have a “sector perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $34.99.
Myriad Genetics (NASDAQ:MYGN) opened at 35.44 on Wednesday. Myriad Genetics has a 52 week low of $20.02 and a 52 week high of $42.50. The stock’s 50-day moving average is $37. and its 200-day moving average is $36.93. The company has a market cap of $2.580 billion and a P/E ratio of 16.08.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 12th. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.46 by $0.02. The company had revenue of $188.80 million for the quarter, compared to the consensus estimate of $187.68 million. Analysts expect that Myriad Genetics will post $1.93 EPS for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Receive News & Ratings for Myriad Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.